Floatz logo

Amt-151

Lung Adenocarcinoma

Multitude Therapeutics Inc.Phase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

67 Active assets in the Lung Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Guangdong Association of Clinical Trials
Phase 3BBB
Cyclophosphamide
Anusha Kalbasi
Phase 2BBB
Nivolumab
Emory University
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
Guangdong Association of Clinical Trials
Phase 3BB
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 3BB

View all 50 →

Same molecule, other indications

Amt-151 is also rated in:

carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
endometrium adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →
endometrial serous adenocarcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →